AWM Investment Company Inc. Acquires 99,594 Shares of 908 Devices Inc. (NASDAQ:MASS)

AWM Investment Company Inc. increased its position in shares of 908 Devices Inc. (NASDAQ:MASS - Free Report) by 6.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,673,924 shares of the company's stock after buying an additional 99,594 shares during the quarter. AWM Investment Company Inc. owned about 4.81% of 908 Devices worth $3,683,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Hsbc Holdings PLC raised its holdings in shares of 908 Devices by 32.2% in the 4th quarter. Hsbc Holdings PLC now owns 21,007 shares of the company's stock worth $46,000 after acquiring an additional 5,112 shares during the last quarter. LPL Financial LLC boosted its holdings in 908 Devices by 13.0% during the 4th quarter. LPL Financial LLC now owns 63,287 shares of the company's stock worth $139,000 after acquiring an additional 7,295 shares during the last quarter. Two Sigma Advisers LP purchased a new stake in shares of 908 Devices in the fourth quarter valued at about $30,000. Geode Capital Management LLC raised its holdings in shares of 908 Devices by 2.4% in the fourth quarter. Geode Capital Management LLC now owns 581,300 shares of the company's stock valued at $1,279,000 after purchasing an additional 13,512 shares during the last quarter. Finally, Northern Trust Corp lifted its position in shares of 908 Devices by 7.5% during the fourth quarter. Northern Trust Corp now owns 200,764 shares of the company's stock valued at $442,000 after purchasing an additional 14,087 shares in the last quarter. Institutional investors own 88.06% of the company's stock.

908 Devices Price Performance

Shares of 908 Devices stock traded up $0.06 during trading hours on Monday, hitting $4.80. 279,729 shares of the company's stock traded hands, compared to its average volume of 999,019. The stock has a market capitalization of $172.13 million, a price-to-earnings ratio of -2.71 and a beta of 0.26. The company has a fifty day simple moving average of $4.64 and a 200-day simple moving average of $3.31. 908 Devices Inc. has a 12-month low of $1.81 and a 12-month high of $6.72.

908 Devices (NASDAQ:MASS - Get Free Report) last released its earnings results on Tuesday, May 13th. The company reported ($0.22) earnings per share for the quarter, beating analysts' consensus estimates of ($0.27) by $0.05. The firm had revenue of $11.78 million during the quarter, compared to the consensus estimate of $11.90 million. 908 Devices had a negative net margin of 109.11% and a negative return on equity of 24.60%. On average, analysts forecast that 908 Devices Inc. will post -1.99 EPS for the current fiscal year.

Insider Transactions at 908 Devices

In other news, Director Mark Spoto acquired 10,000 shares of the business's stock in a transaction dated Wednesday, May 14th. The stock was bought at an average cost of $4.29 per share, for a total transaction of $42,900.00. Following the completion of the transaction, the director now owns 62,971 shares of the company's stock, valued at $270,145.59. The trade was a 18.88% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 27.70% of the company's stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of 908 Devices in a research report on Saturday, May 10th. Two analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $5.33.

908 Devices Profile

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.